References
- VANE JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature (1971) 231:232–235.
- ALLISON MC, HOWATSON AG et al.: Gastrointestinal damage associated with the use of non-steroidal anti-inflammatory drugs. New Engl.J. Med. (1992) 327:749–754.
- GANS KR, GALBRAITH W et al.: Anti-inflammatory and safety profile of DuP-697, a novel orally effective pro-staglandin synthesis inhibitor. J. Pharmacol. Exp. Ther. (1990) 254:180–187.
- LI JJ, ANDERSON GD et al.: 1,2-diarylcyclopentenes asselective cyclooxygenase-2 inhibitors and orally active anti-inflammatory agents. J. Med. Chem. (1995) 38:4570–4578.
- SEIBERT K, ZHANG Y et al.: Pharmacological and bio-chemical demonstration of the role of cyclooxygenase-2 in inflammation and pain. Proc. Natl. Acad. Sci. USA (1994) 91:12013–12017.
- LI JJ, NORTON MB et al.: Novel terphenyls as selective cyclooxygenase-2 inhibitors and orally active anti-in-flammatory agents. J. Med. Chem. (1996) 39:1846–1856.
- COPELAND RA, WILLIAMS .Th4 et al.: Selective time-de-pendent inhibition of cyclooxygenase-2. Med. Chem. Res. (1995) 5:384–393.